
Alexander Baldacchino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2503472/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chronic pain, prescribed opioids and overdose risk: a qualitative exploration of the views of affected individuals and family members. Drugs: Education, Prevention and Policy, 2023, 30, 229-240.	1.3	2
2	Professionals' Digital Training for Child Maltreatment Prevention in the COVID-19 Era: A Pan-European Model. International Journal of Environmental Research and Public Health, 2022, 19, 885.	2.6	8
3	Development of an algorithm to classify primary care electronic health records of alcohol consumption: experience using data linkage from UK Biobank and primary care electronic health data sources. BMJ Open, 2022, 12, e054376.	1.9	1
4	A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus. Nature Protocols, 2022, 17, 567-595.	12.0	26
5	Harm reduction and abstinence-based models for treatment of substance use disorders during the COVID-19 pandemic: a global perspective. BJPsych International, 2022, 19, 66-69.	1.4	9
6	Protracted abstinence in males with an opioid use disorder: partial recovery of nucleus accumbens function. Translational Psychiatry, 2022, 12, 81.	4.8	6
7	Why Do Different Forms of Knowledge Matter in Evidence-Based Drug Policy?. American Journal of Public Health, 2022, 112, S140-S142.	2.7	0
8	Ophthalmic outcomes in children exposed to opioid maintenance treatment in utero: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2022, 136, 104601.	6.1	5
9	Chronic heroin use disorder and the brain: Current evidence and future implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110148.	4.8	12
10	Alcohol Binge Drinking: Negative and Positive Valence System Abnormalities. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 126-134.	1.5	9
11	An international consultation on case reports in addiction medicine. Substance Abuse, 2021, 42, 1-7.	2.3	0
12	Using Microdosing to Induct Patients Into a Long-Acting Injectable Buprenorphine Depot Medication in Low Threshold Community Settings: A Case Study. Frontiers in Pharmacology, 2021, 12, 631784.	3.5	9
13	Adherence to Prescribed Acamprosate in Alcohol Dependence and 1-Year Morbidities and Mortality: Utilizing a Data Linkage Methodology. Journal of Clinical Medicine, 2021, 10, 2102.	2.4	2
14	Association between chronic psychoactive substances use and systemic inflammation: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2021, 125, 208-220.	6.1	13
15	Quantifying prescribed high dose opioids in the community and risk of overdose. BMC Public Health, 2021, 21, 1174.	2.9	6
16	Baseline executive functions and receiving cognitive rehabilitation can predict treatment response in people with opioid use disorder. Journal of Substance Abuse Treatment, 2021, 131, 108558.	2.8	7
17	Understanding Fatal and Non-Fatal Drug Overdose Risk Factors: Overdose Risk Questionnaire Pilot Study—Validation. Frontiers in Pharmacology, 2021, 12, 693673.	3.5	2
18	Neurocognitive consequences of chronic cannabis use: a systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2020, 108, 358-369.	6.1	67

#	Article	IF	CITATIONS
19	Cognitive consequences of opioid use. , 2020, , 179-198.		0
20	COVID-19 and Substance Use Disorders as Brain Diseases: Recommendations to a Comprehensive Healthcare Response. An International Society of Addiction Medicine (ISAM) Practice and Policy Interest Group Position Paper. Basic and Clinical Neuroscience, 2020, 11, 133-150.	0.6	74
21	Psychological Impact of the Acute COVID-19 Period on Patients With Substance Use Disorders: We Are All in This Together. Basic and Clinical Neuroscience, 2020, 11, 207-216.	0.6	26
22	COVID-19 and Substance Use Disorder: Study Protocol for the International Society of Addiction Medicine Practice and Policy Interest Group Global Survey. Basic and Clinical Neuroscience, 2020, 11, 155-162.	0.6	5
23	Is (poly-) substance use associated with impaired inhibitory control? A mega-analysis controlling for confounders. Neuroscience and Biobehavioral Reviews, 2019, 105, 288-304.	6.1	42
24	Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice. Frontiers in Psychiatry, 2019, 10, 592.	2.6	71
25	Compulsivity in opioid dependence. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 81, 333-339.	4.8	22
26	Alcohol policies in Malawi: inclusion of WHO "best buy―interventions and use of multi-sectoral action. BMC Public Health, 2018, 18, 957.	2.9	12
27	Investigating the effect of Alcohol Brief Interventions within accident and emergency departments using a data informatics methodology. Drug and Alcohol Dependence, 2018, 188, 47-52.	3.2	2
28	Engagement in the Overdose RIsk InfOrmatioN (ORION) e-Health Tool for Opioid Overdose Prevention and Self-Efficacy: A Preliminary Study. Cyberpsychology, Behavior, and Social Networking, 2017, 20, 762-768.	3.9	11
29	Abnormal Brain Activity During a Reward and Loss Task in Opiate-Dependent Patients Receiving Methadone Maintenance Therapy. Neuropsychopharmacology, 2014, 39, 885-894.	5.4	54
30	Neurobehavioral consequences of chronic intrauterine opioid exposure in infants and preschool children: a systematic review and meta-analysis. BMC Psychiatry, 2014, 14, 104.	2.6	95
31	Association between depression and non-fatal overdoses among drug users: A systematic review and meta-analysis. Drug and Alcohol Dependence, 2014, 134, 12-21.	3.2	46
32	Co-morbidity of substance use and mental disorders. What do we know on the prevalence of psychiatric comorbidity in Europe and what are the ways forward?. Mental Health and Substance Use: Dual Diagnosis, 2013, 6, 97-100.	0.5	1
33	A comparison of accidental and intentional fatal drug overdoses within the drug death population in Scotland: a case of comortality?. Mental Health and Substance Use: Dual Diagnosis, 2011, 4, 5-21.	0.5	Ο
34	Pathways through care for people with dual diagnosis in Europe: results from the Treatment Options for Dual Diagnosis User Zoom instrument. Mental Health and Substance Use: Dual Diagnosis, 2011, 4, 195-210.	0.5	4
35	Guilty until proven innocent: A qualitative study of the management of chronic non-cancer pain among patients with a history of substance abuse. Addictive Behaviors, 2010, 35, 270-272.	3.0	74
36	Co-Morbid Substance Misuse and Mental Health Problems: Policy and Practice in Scotland. American Journal on Addictions, 2007, 16, 147-159.	1.4	8

#	Article	IF	CITATIONS
37	Internet pharmacies and online prescription drug sales: a cross-sectional study. Drugs: Education, Prevention and Policy, 2005, 12, 75-80.	1.3	66